Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). To date, no prophylactic vaccines or approved therapeutic agents are available for preventing and treating this highly transmittable disease. Here we report two monoclonal antibodies (mAbs) cloned from memory B cells ...
of patients recently recovered from COVID-19, and both mAbs specifically bind to the spike (S) protein of SARS-CoV-2, block the binding of receptor binding domain (RBD) of SARS-CoV-2 to human angiotensin converting enzyme 2 (hACE2), and effectively neutralize S protein-pseudotyped virus infection. These human mAbs hold the promise for the prevention and treatment of the ongoing pandemic of COVID-19.
Mesh Terms:
Adult, Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Cloning, Molecular, HEK293 Cells, Humans, Protein Binding, Receptor, Angiotensin, Type 2, Spike Glycoprotein, Coronavirus
Cell Mol Immunol
Date: Dec. 01, 2019
Download Curated Data For This Publication
221565
Switch View:
  • Interactions 1